AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...

Amgen reported yesterday that full-year 2023 sales of Lumakras were $280 million, a dip on the prior year, while Mirati ... KRAS category comes shortly after AstraZeneca licensed a KRAS G12D ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56 LONDON, September 09, 2024--Silexion Therapeutics (NASDAQ ...

Co-opted Pathways Required by Oncogenic KRAS to Sustain Lung Tumorigenesis Oncogenic KRAS relies on additional pathways that are engaged downstream of these effectors or are required indirectly as ...

Using single-cell RNA and ATAC sequencing in Kras/p53-driven tumor organoids, we identified two major cellular states: one more closely resembling alveolar type 2 (AT2) cells (SPC-high), and the other ...

After hours: February 10 at 5:00:28 PM EST Loading Chart for GDTC ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After hours: 7:47:57 pm GMT-5 ...